Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Epix Will Resubmit Vasovist NDA By Mid-Year

This article was originally published in The Pink Sheet Daily

Executive Summary

End appears near in long road to approval for vascular imaging agent after FDA and Epix agree on plan for Phase III study image re-reads.

You may also be interested in...



Epix Expanded Agreement With Cystic Fibrosis Foundation Valued At $50 Million

Extended deal includes potential for $37.7 million in payments to Epix, which is developing 3-D model of key protein associated with CF.

Epix Expanded Agreement With Cystic Fibrosis Foundation Valued At $50 Million

Extended deal includes potential for $37.7 million in payments to Epix, which is developing 3-D model of key protein associated with CF.

Epix Drops Depression Candidate After Second Study Failure

Alzheimer’s candidate in development with GlaxoSmithKline advances.

Related Content

Topics

UsernamePublicRestriction

Register

PS067213

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel